Biotechnology

Biotech

Prothena scraps lead drug following mid-stage study failure

By Adam Feuerstein

The Readout LOUD

LISTEN: The Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism

By Damian Garde and Rebecca Robbins

Dr. John Maraganore
Biotech

Trade secrets battle between Alnylam, Dicerna is just one of many

By Jonathan Saltzman — Boston Globe

Money
Business

How well do biotech and pharma pay? A breakdown by company

By Damian Garde

The Readout LOUD

LISTEN: Biotech buyouts, CEO breakups, and The Rock does CRISPR

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Elizabeth Holmes
Business

‘Therabros’ and ‘disappeared’ staffers: the 8 juiciest things we learned from John Carreyrou’s new Theranos book

By Rebecca Robbins

Adam's Take

Biogen and the badly needed gene therapy acquisition that got away

By Adam Feuerstein

David Hung
Biotech

The stint that never happened? Biotech vet David Hung wipes Axovant from his work history

By Damian Garde

AP
Biotech

Incyte’s cancer drug fails trial, marking major blow for immunotherapy combination treatment

By Adam Feuerstein

Medicine
Pharma

Drug makers have to post policies for patients seeking experimental medicines. Not all do

By Erin Mershon

CAR-T
Biotech

They built a game-changing cancer-killing therapy. Now they’re taking on a new kind of CAR-T therapy

By Rebecca Robbins

Stock Market
Biotech

The biotech scorecard for the 2nd quarter: 12 make-or-break industry events to watch

By Adam Feuerstein

The Readout LOUD

LISTEN: A billionaire intervenes, inscrutable drug prices, and no grade inflation for biotechs

By Rebecca Robbins and Adam Feuerstein

Texas Medical Center in Houston
Biotech

Houston aspires to become the ‘third coast’ of biotech. Can it pull it off?

By Andrew Joseph

Adam's Take

Biotech saw positive results this quarter; shares still tanked. Here are some explanations

By Adam Feuerstein

Moderna sign
Exclusive

Here’s the slide deck Moderna uses to defend its $7.5 billion valuation

By Damian Garde

Biotech column IMAGE
Biotech

Biohaven migraine pill achieves main goals in late-stage clinical trials, but stock still plunges

By Adam Feuerstein and Damian Garde

Wyss Immunotherapy - PLG Scaffold
In the Lab

Cancer immunotherapy implants get boost by Novartis licensing

By Elizabeth Cooney

The Readout LOUD

LISTEN: An eyewitness gene therapy story, breaking down Incyte’s future, and was Gottlieb wrong to try?

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Mouse running
In the Lab

A dietary supplement makes old mice youthful. But will it work in people?

By Sharon Begley

Vials
Biotech

Buried in spending package: a big win for a small drug company

By Erin Mershon

Jack Hogan
Biotech

‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price

By Eric Boodman

HOLMES & Balwani
Business

Theranos’s mystery man revealed: Rare footage of Sunny Bawlani was hiding in plain sight

By Rebecca Robbins

HOLMES & Balwani HP
Business

Investigators say his fingerprints are all over financial crimes at Theranos. Why is he a virtual ghost?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

The Readout LOUD

LISTEN: Theranos’s fate, biotech’s awkward SXSW, and a word on cow loogies

By Damian Garde

Arbor
Biotech

Stealth biotech Arbor steps out of the shadows, announcing it’s found a new CRISPR enzyme

By Sharon Begley

SXSW Film Opening Night Party
Biotech

Biotech tries to break bread with Silicon Valley’s disruptors. It’s awkward

By Damian Garde

Hepatitis Drugs
Business

End of an era: Gilead’s longtime R&D chief is stepping down at a pivotal moment for the company

By Rebecca Robbins

Sarepta
Biotech

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.